NIH Requests Applications for Clinical Studies of Milk Thistle in Chronic Liver Disease

Milk thistle plant

Milk thistle is a flower, a member of the aster family. Its seeds and roots have been used for an assortment of medical purposes for hundreds of years. Three biochemicals have been isolated from the milk thistle: silychristine, silydianin, and silybin. The mixture of these three substances is called “silymarin.” 

Silymarin traditionally has been used in the treatment of liver disease and, while it has recently been advocated for use in pets, most of the information available about it concerns human use. The biological mechanism of action of milk thistle is unknown.

The National Institutes of Health have a keen interest in studying the potential benefits of silymarin on the liver. In the article that follows, published in the July 2005 issue of Hepatology, J H Hoofnagle, MD, of the Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)  writes about the NIH-initiated effort to conduct the first scientifically rigorous study of silymarin.

Milk thistle has been used for centuries to treat acute and chronic liver diseases and, even today, is one of the most widely used herbal medications. Its active ingredients appear to be several closely related flavinoids, collectively known as silymarin.

Most silymarin preparations have at least a dozen molecular components and their isomers, including silybin, isosilybin, cis-silybin, silydianin, and silychristine. It is not clear whether one, several, or all of these components are the active ingredient(s), and most commercial preparations represent rough extracts of the milk thistle plant (Silybum Marianum) rather than a purified subcomponent.

Results of studies in experimental animal models suggest that silymarin has a broad spectrum of hepatoprotective effects. Thus, silymarin can protect experimental animals against injury from several toxins, including amanita phalloides, carbon tetrachloride, ethanol, and galactosamine. Silymarin is partially protective even when given after exposure.

The basis for this hepatoprotective activity may be the antioxidant qualities of the several flavinoids, but antifibrotic, antiinflammatory and immune modulatory actions of silymarin may also be important.

A safe and effective, broad-spectrum hepatoprotective agent would likely be very useful in the management of liver disease. Yet, despite its clear effects in experimental animal models, silymarin has yet to be proven effective in ameliorating human liver disease. Part of the problem is that silymarin has never been adequately evaluated using objective and clinically meaningful endpoints in well-characterized cohorts of patients with well-defined forms of liver disease.

Because of its safety, lack of side effects, activity in animal models, and centuries-long traditional use in liver disease, milk thistle has been introduced and is widely used as an herbal preparation in the United States. It is available in most health food stores and in many conventional grocery stores where it is advertised as beneficial for the liver or for "liver wellness."

Food and Drug Administration (FDA) rules prohibit the advertisement of any agent as a specific therapy for liver disease, unless it has been proven to be safe and effective, in which case it would be regulated as a drug rather than an herbal preparation.

In surveys conducted in liver disease clinics, between 10% and 15% of patients report taking milk thistle, almost entirely on the basis of advice from friends, magazine articles, or the Internet rather than on advice of a physician.

Clearly, proof of the efficacy of milk thistle preparations (or lack thereof) and further documentation of its safety are critical needs in improving management of liver disease. In the recently published Action Plan for Liver Disease Research, evaluation of nonspecific hepatoprotective agents such as silymarin was listed as an unmet and important research goal.

To address these issues, the National Center for Complementary and Alternative Medicine (NCCAM)   in collaboration with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) held a research workshop entitled "Silymarin for Chronic Liver Disease".  

In this workshop, two critical first steps for development of silymarin as a therapy for liver disease were defined: (1) to identify a standard, reliable silymarin product that could be used in clinical investigation and (2) to initiate phase I/II trials of this product in liver disease.

Disease conditions that were considered most appropriate for evaluation were nonalcoholic steatohepatitis (NASH) and chronic hepatitis C, with particular focus on patients who were nonresponders to conventional therapy. The goals for pilot, phase I/II studies were to define the optimal dose and dosing regimen for silymarin and to identify the appropriate patient cohorts and surrogate markers for assessment of efficacy and safety.

These elements were considered critical, before expensive, definitive trials of silymarin therapy were initiated that might depend upon more long-term therapy and more critical clinical endpoints.

Accordingly, in March 2005, NCCAM published an announcement of availability of an industry collaboration for the development and evaluation of a commercial form of silymarin.

This announcement requested a partnership with a commercial entity that could provide a well-characterized, standard formulation of silymarin that could be evaluated in humans under an FDA-approved Investigational New Drug (IND) Application.

Finally, in June 2005, NCCAM and NIDDK published a Request for Applications for a Silymarin Clinical Research Consortium. The Consortium will consist of approximately four Clinical Centers and a single Data Coordinating Center, which would be charged with the design and conduct of phase I/II clinical trials of silymarin in NASH and chronic hepatitis C.

Each applicant for a Clinical Center is asked to document their experience in participating in multi-center clinical trials, experience in evaluation and follow-up of patients with liver disease, and insight and knowledge about design and conduct of phase I/II clinical trials.

Applicants for the Data Coordinating Center are asked to document experience with managing multi-center clinical trials and data acquisition, management and analysis. A letter of intent is requested by August 15, 2005 and final applications by September 12, 2005. Applicants are limited to the United States.   Link to details of the RFA.

06/29/05

Source
J H Hoofnagle. Milk thistle and Chronic Liver Disease. Hepatology 42(1): 4-4. July 2005.

Additional Liver-related Topics
Liver Biopsy
Cirrhosis
Fibrosis
Hepatic Decompensation
Hepatic Failure
Hepatocellular Carcinoma
Histology
Liver Stiffness Measurement (LSM)
Liver Transplantation
Non-Alcoholic Fatty Liver Disease (NAFLD)
Risk Factors for HCC
SENV
Steatosis
The Liver: Anatomy and Functions

All HCV Topics  [ A to Z ]

2-log Drop
Acute (Primary) HCV Infection
Age
Alcohol / Smoking / Diabetes
ALT
Anemia
Children
Chronic HCV Infection
Cirrhosis
Cognitive Behavioral Therapy
Complementary Therapies (CAM)
Combination Treatment
Cryoglobulinemia / Cryoglobulin
Disease Progression
Decompensation
Developing Countries
Depression
Diabetes Mellitus
Dosing
Drug Abuse
Drug Pricing
Drug Related Adverse Events
Early Treatment Cessation
Early Virologic Response
Epidemiology / African Americans
Epoetin Alpha
Early Viral Response (EVR)
Eradication
Extrahepatic Events
Experimental Treatment
Experimental Therapy (procedure)
Fibrosis
Gender
Genetics
Genotype 1 and 4
Genotype 2 and 3
Genotype 5 and 6
GGT Levels
Glucose Intolerance
Growth Factors
Guidelines
HCV Clearance
HCV Disease Progression
HCV-Drug Related Adverse Events
HCV Recurrence After Transplantation
Hearing
Hematological Growth Factors
Hemodialysis
Hemoglobin
Hemophilia
Hepatic Decompensation
Hepatic Failure
Hematological Disorders
Hepatocellular Carcinoma
Histology
Hormone Therapies
hyaluronate (HA)
Immunoglobulins
Immunosuppression
Induction Therapy
Injection Drug Use
Infergen
Insulin Resistance
Interferon
Interferon Resistance
Intron A
Kidney Disorders
Kidney Transplant
Liver Biopsy
Liver Enzymes
Liver Issues
Living Donors
Liver Stiffness Measurement (LSM)
Maintenance Therapy
Methadone
Miscellaneous
Mortality and Morbidity
Monotherapy Treatment
Mother to Child Transmission of HCV
Natural History
Neutropenia
Non-Alcoholic Fatty Liver
  Disease (NAFLD)
Non-Hepatic Cancers
Non-Hodgkins Lymphoma
Non-organ Specific Autoantibodies
Nonresponders / Relapsers
Obesity
Occult HBV Infection
Pathogenesis
Pegasys
PEG-Intron
Pegylated Inferferon
Pharmacokinetics
Platelets
Pregnancy
Productivity
PIIINP/MMP-1, prothrombin time (PT)
Quality of Life
Quasispecies
Rapid Virologic Response (RVR)
Recurrent HCV
Re-Treatment
Retinopathy
Ribavirin
Ribavirin Dosing
Risk Factors for HCC
Risk Factors
Roferon
Seroconversion
Sex (gender)
Sexual Transmission
Skin Reactions / Diseases
Sleeplessness
Steatosis
Steroids
Superinfection
Survival
Sustained Viral Response
Toxicities and Side Events
Transmission
Transplantation
Undetectable HCV RNA
Viral Eradication
Viral Kinetics
Viral Load
Weight-based Dosing
Women and Children